Browse Technologies

• 
• 
• 
• 

This technology uses a novel continuum robot that provides a steerable channel to enable safe surgical access to the anatomy of a patient. This robotic device has a wide range of clinical application and is a significant advance from the rigid tools currently used in minimally invasive procedures.

This technology, developed in Vanderbilt University's Advanced Robotics and Mechanism Applications Laboratory, uses a minimally invasive telerobotic platform to perform transurethral procedures, such as transurethral resection. This robotic device provides high levels of precision and dexterity that improve patient outcomes in transurethral procedures.

New compounds developed at Vanderbilt demonstrate a unique mechanism of broad spectrum activity to stymy antibacterial resistance. The compounds are particularly useful in chronic infections where long term antibiotic therapy fails, because it specifically kills "small colony variants" -- the bacteria that have developed resistance mechanisms. These compounds show promise in treating Methicillin-resistant S. aureus (MRSA), Bacillus anthracis (anthrax), and in overcoming difficult-to-treat infections in bone in cystic fibrosis patients. These compounds could be combined with new (and old) antimicrobial drugs to outwit resistant bacterial infections.

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.